Stay up to date with notifications from The Independent

Notifications can be managed in browser preferences.

Gene may hold key to mystery of depression

Lucy Christie
Friday 18 November 2005 01:00 GMT
Comments

Your support helps us to tell the story

From reproductive rights to climate change to Big Tech, The Independent is on the ground when the story is developing. Whether it's investigating the financials of Elon Musk's pro-Trump PAC or producing our latest documentary, 'The A Word', which shines a light on the American women fighting for reproductive rights, we know how important it is to parse out the facts from the messaging.

At such a critical moment in US history, we need reporters on the ground. Your donation allows us to keep sending journalists to speak to both sides of the story.

The Independent is trusted by Americans across the entire political spectrum. And unlike many other quality news outlets, we choose not to lock Americans out of our reporting and analysis with paywalls. We believe quality journalism should be available to everyone, paid for by those who can afford it.

Your support makes all the difference.

The discovery of a gene linked to depression is a step towards solving the mystery of mental illness, researchers say. They believe it could lead to the development of drugs to cure the condition, along with schizophrenia and bipolar disorder.

Scientists at Glasgow and Edinburgh universities found that damage to the gene, which is known as PDE4B, can increase the risk of depression. The gene helps the brain think and builds memories, but had not been linked to mental disorder.

Professor David Porteous at the University of Edinburgh said: "This is another important breakthrough in our still limited understanding of major mental illness. It is the result of a long-term research commitment to use the tools of genetics to better understand the root causes of mental disorder. It also suggests a new way of thinking about developing better medicines."

The discovery was made by researchers working with scientists from the pharmaceutical firm Merck Sharpe and Dohme.

Join our commenting forum

Join thought-provoking conversations, follow other Independent readers and see their replies

Comments

Thank you for registering

Please refresh the page or navigate to another page on the site to be automatically logged inPlease refresh your browser to be logged in